Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Soliris eculizumab: Additional Phase III data

Additional data from the open-label, international Phase III SHEPHERD trial in 97 patients showed that Soliris reduced

Read the full 174 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE